Short answer
Nkarta, Inc. (NKTX) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for the quarter ended September 30, 2026.
Nkarta, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for the quarter ended September 30, 2026
- Full operating and financial details available in Exhibit 99.1, the company’s earnings press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 net loss $33.3M, or $0.45 per share, versus $21.7M, or $0.29, in Q3 2025
- R&D spending rose to $29.5M from $20.2M, reflecting accelerated NKX019 clinical development
- Cash, restricted cash and investments totaled $216.0M, with management projecting funding into 2029
- Initial NKX019 clinical data in myositis and systemic sclerosis scheduled for ACR Convergence 2026
- Ntrust dosing uses 4 billion cells per dose across 3 doses, totaling 12 billion cells per patient cycle
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nkarta, Inc. 8-K filings
Get the next NKTX 8-K as it lands
Follow NKTX for push alerts, or ask the research agent what this filing means.